Seong-jin Kim, the CEO of MedPacto, unveils innovative new drug candidate at the Korean Society for Bone and Mineral Research
May 22, 2023
Targeting bone diseases and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoporosis
[2023-05-22] MedPacto (CEO Seong-jin Kim), a genome-based drug discovery and a clinical-stage biotechnology company, presented its innovative new drug candidate for bone diseases during the 35th Spring Conference of the Korean Society for Bone and Mineral Research. The conference took place at the Grand Walker hill Hotel in Seoul from the 18th to the 20th.
On the 20th, the last day of the conference, Seongjin Kim, CEO of MedPacto, introduced ‘MP2021’, an innovative new drug candidate for bone diseases being developed by MedPacto. The introduction took place during a session with the theme of ‘Latest Research on Bone Cell Biology’. In his presentation, CEO Kim elaborated on the mechanism of action and therapeutic effect of MP2021.
MP2021 is a new drug candidate targeting bone diseases and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoporosis.
Human bones contain osteoclasts in the bone marrow, which, when they undergo differentiation into multinucleated osteoclasts, erode the bones. This process is a significant contributor to bone diseases like rheumatoid arthritis and osteoporosis. MP2021 is an innovative new drug candidate that functions by blocking osteoclast multinucleation and inhibiting bone differentiation.
In contrast to other treatments like Humira, MP2021 works differently. Instead of inhibiting inflammation or osteoclast growth factors, it specifically targets the prevention of multiple osteoclast formation, which is responsible for bone erosion.
Medpacto has completed animal testing for MP2021, and toxicity testing is currently underway in Europe. Moreover, the company has successfully completed the international patent application (PCT) for MP2021.
The Korean Society for Bone and Mineral Research is a prestigious academic research organization dedicated to promoting the progress of medicine and national health through academic exchanges and research on musculoskeletal metabolic diseases, such as osteoporosis. During this Spring Conference, esteemed scholars specializing in musculoskeletal disorders from around the globe were invited, alongside prominent academic figures from both domestic and international backgrounds, to deliver a total of 70 presentations across 35 sessions.